Ezrin在浆液性卵巢癌中的表达及临床意义

谢哲 李兰芳 罗清雅 刘毅 李贵琴 王耕超 毛成毅 易萍*

doi:10.16098/j.issn.0529-1356.2017.01.010

PDF(505 KB)

解剖学报 ›› 2017, Vol. 48 ›› Issue (1) : 54-60. DOI: 10.16098/j.issn.0529-1356.2017.01.010

肿瘤生物学

Ezrin在浆液性卵巢癌中的表达及临床意义

谢哲¹ 李兰芳¹罗清雅² 刘毅¹李贵琴¹ 王耕超³毛成毅² 易萍^1*

作者信息 +

Expression and clinical significance of Ezrin in the serous ovarian cancer

XIE Zhe¹ LI Lan-fang¹LUO Qing-ya² LIU Yi¹ LI Gui-qin¹ WANG Geng-chao³ MAO Cheng-yi²YI Ping^1*

Author information +

文章历史 +

摘要

目的通过检测 Ezrin在正常卵巢上皮和浆液性卵巢癌组织中的差异表达，探讨其对浆液性卵巢癌发生发展的影响。方法收取浆液性卵巢癌冷冻组织40例，正常卵巢上皮27例，提取总RNA，采用Real-time PCR技术检测Ezrin mRNA在两组样本中的表达差异；选取有完整临床病理资料的浆液性卵巢癌石蜡包埋组织134例，以及27例非卵巢癌病例的卵巢上皮组织，通过免疫组织化学染色检测两组样本中Ezrin蛋白质的表达差异，并应用SPSS 20.0软件分析其与临床病理的相关性。结果 Ezrin mRNA在新鲜卵巢癌组织中的表达显著低于正常卵巢上皮组织（P<0.05）。Ezrin蛋白在石蜡包埋卵巢癌组织中也相应降低（P<0.05)。Ezrin蛋白质表达水平与年龄、手术满意程度及化疗敏感程度无相关性，与细胞分化、病理分期及大网膜转移显著相关，（P<0.05)。Ezrin表达水平高的浆液性卵巢癌病例的无进展生存期（PFS）值和总生存期（OS）值都明显高于表达水平低的病例（P<0.05)。但Ezrin并不能作为浆液性卵巢癌的独立预后因素。结论 Ezrin的表达下调与浆液性卵巢癌的发生发展、转移等病理过程相关，其可以作为临床预后的潜在指标。

Abstract

Objective To investigate the expression feaure of Ezrin in the normal ovarian epithelial tissues and the serous ovarian cancer tissues and evaluate the relationships between Ezrin expression and the clinicopathological characteristics of ovarian cancer patient. Methods The relative Ezrin mRNA- expression was detected by Real-time PCR in 40 specimens of ovarian carcinoma and 27 specimens of normal ovarian epithelial fresh frozen tissues. A total of 134 specimens of paraffin-embeded ovrian cancer tissues and 27 specimens of normal ovarian epithelial tissues were collected,and the Ezrin protein level was examined by immunohistochemistry. The correlation of Ezrin with the clinicopathological characteristics of patients with ovarian cancer was analyzed by SPSS 20.0. Results Both the RNA and protein levels of Ezrin were significantly reduced in ovarian cancer compared to the normal control(P<0.05). Statistical analysis revealed that Ezrin expression had no correlation with age, cytoreduction satisfactory degree and sensitivity of chemotherapy. However there was a significant difference in ezrin protein levels with the disease-free and overall survival (P<0.05). Although ezrin did not serve as an independent predictor for disease progression (HR 1.406, P>0.05) and overall survival (HR 1.260, P>0.05), the expression of Ezrin was negatively correlated with clinical stage,differentiation, and Oentum majus metastasis (P<0.05). Conclusion The down-regulation of Ezrin may play a substantial role in the pathophysiology of serous ovarian cancer. Therefore, it may be used as the potential pre-diagnostic and prognostic marker of ovarian cancer and direct the clinical treatment in the future.

导出引用

谢哲李兰芳罗清雅刘毅李贵琴王耕超毛成毅易萍. Ezrin在浆液性卵巢癌中的表达及临床意义[J]. 解剖学报. 2017, 48(1): 54-60 https://doi.org/10.16098/j.issn.0529-1356.2017.01.010

XIE Zhe LI Lan-fang LUO Qing-ya LIU Yi LI Gui-qin WANG Geng-chao MAO Cheng-yi YI Ping. Expression and clinical significance of Ezrin in the serous ovarian cancer[J]. Acta Anatomica Sinica. 2017, 48(1): 54-60 https://doi.org/10.16098/j.issn.0529-1356.2017.01.010

参考文献

［1］Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］. CA Cancer J Clin, 2011, 61(4): 212-236.

［2］Liang XD, Zeng HX, Zhu HL, et al. Platinum-resistance in advanced epithelial ovarian carcinomas and treatment for different recurrent diseases［J］. Progress in Obstetrics and Gynecology, 2011, 20(11): 841-845. (in Chinese)

梁旭东, 曾浩霞, 祝洪澜, 等. 晚期卵巢上皮癌耐药分析及复发后治疗［J］. 现代妇产科进展, 2011, 20(11): 841-845.

［3］English DP, Menderes G, Black J, et al. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer［J］. Expert Rev Mol Diagn, 2016, 16(7): 769-782. ［4］Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors［J］. Semin Surg Oncol, 2000, 19(1): 3-10.

［5］Jacobs I, BR Jr. The CA 125 tumour-associated antigen: a review of the literature［J］. Hum Reprod, 1989, 4(1): 1-12.

［6］Ponuwei GA. A glimpse of the ERM proteins［J］. J Biomed Sci, 2016, 23(1): 1-6

［7］Arpin M, Chirivino D, Naba A, et al. Emerging role for ERM proteins in cell adhesion and migration［J］. Cell Adh Migr, 2011, 5(2): 199-206.

［8］Konstantinovsky S, Davidson B, Reich R. Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids［J］. Clin Exp Metastasis, 2012, 29(6): 527-540.

［9］Hunter KW. Ezrin, a key component in tumor metastasis［J］. Trends Mol Med, 2004, 10(5): 201-204.

［10］Meng Y, Lu Z, Yu S, et al. Ezrin promotes invasion and metastasis of pancreatic cancer cells［J］. J Transl Med, 2010, 8(1): 274-276.

［11］Shang X, Wang Y, Zhao Q, et al. siRNA-s target sites selection of ezrin and the influence of RNA- interference on ezrin expression and biological characters of osteosarcoma cells［J］. Mol Cell Biochem, 2012, 364(1): 363-371

［12］Li Q, Gao H, Xu H, et al. Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells［J］. Tumour Biol, 2012, 33(5): 1493-1504.

［13］Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators［J］. Nat Med, 2004, 10(2): 175-181.

［14］Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis［J］. Nat Med, 2004, 10(2): 182-186.

［15］Weng WH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas［J］. Clin Cancer Res, 200511(17): 6198-6204.

［16］Kobel M, Langhammer T, Huttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas［J］. Mod Pathol, 2006, 19(4): 581-587.

［17］Abdou AG, Sakr S, Elwahed MM, et al. Immunohistochemical assessment of ezrin and moesin in colorectal carcinoma［J］. Ultrastruct Pathol, 2016, 40(4): 1-8.

［18］Hiscox S, Jiang WG. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin［J］. J Cell Sci, 1999, 112(18): 3081-3090.

［19］Chen Z, Fadiel A, Feng Y, et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor［J］. Cancer, 2001, 92(12): 3068-3075.

［20］Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients［J］. Gynecol Oncol, 2003, 90(2): 273-281.

［21］Zhou J, Liu H, Chen Y, et al. Expression and significance of VEGF, miR-205 and target protein Ezrin and Lamin A/C in ovarian cancer［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39(2): 142-150.